1MAUDE S L, FREY N, SHAW P A, et al. Chimeric antigen T cells for sustained remissions in leukemia [J]. The New England Journal of Medicine, 2014, 371(16): 1507-1517.
2HEUSER C, HOMBACH A, LOSCH C, et al. T-cell activation by recombinant immunore ceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-speciic activation of grafted T cells [J]. Gene Therapy, 2003, 10(17): 1408-1419.
3ZHAO Y, WANG Q J, YANG S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity [J]. The Journal of Immunology, 2009, 183(9): 5563-5574.
4PEGRAM H J, PARK J H, BRENTJENS R J. CD28z CARs and armored CARs [J].The Cancer Journal, 2014, 20(2): 127-133.
5MORGAN R A, YANG J C, KITANO M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 [J]. Molecular Therapy, 2010, 18(4): 843- 851.
